Scarica l'app Stockscreener
33.13
6.28%
-2.22
Dopo l'orario di chiusura:
33.13
Precedente Chiudi:
$35.35
Aprire:
$34.85
Volume 24 ore:
1.56M
Relative Volume:
1.07
Capitalizzazione di mercato:
$2.62B
Reddito:
-
Utile/perdita netta:
$-119.67M
Rapporto P/E:
-12.14
EPS:
-2.73
Flusso di cassa netto:
$-97.30M
1 W Prestazione:
-8.71%
1M Prestazione:
-13.27%
6M Prestazione:
+137.49%
1 anno Prestazione:
+195.80%
Intervallo 1D:
$32.61
$35.28
Intervallo di 1 settimana:
$32.61
$37.70
Portata 52W:
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER ROAD, RADNOR
Confronta MLYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
33.13 | 2.80B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Will Mineralys Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Final Week & High Conviction Investment Ideas - ulpravda.ru
Can Mineralys Therapeutics Inc. stock attract ESG capital inflowsEarnings Risk Summary & Weekly Breakout Watchlists - ulpravda.ru
Is Mineralys Therapeutics Inc. stock a contrarian buyJuly 2025 Breakouts & Verified Momentum Watchlists - ulpravda.ru
Why Mineralys Therapeutics Inc. stock could outperform in 2025Quarterly Growth Report & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Mineralys Flags Key Data Readouts as Lorundrostat Nears FDA Decision - MyChesCo
Mineralys Therapeutics Insider Sold Shares Worth $9,261,028, According to a Recent SEC Filing - MarketScreener
Mineralys Therapeutics: Lorundrostat’s Broad Efficacy, Favorable Safety, and Upside Indications Support Buy Rating on MLYS - TipRanks
Mineralys Therapeutics filed NDA for lorundrostat to U.S. FDA in late 2025 - MarketScreener
Mineralys updates lorundrostat program and upcoming data milestones - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Investor Outlook: Analyzing a Potential 42.67% Upside in the Biotech Sector - DirectorsTalk Interviews
Mineralys Therapeutics, Inc. Provides Corporate Update and Announces NDA Filing - TradingView — Track All Markets
New blood pressure drug shows promise for hard-to-treat patients - Stock Titan
Will Mineralys Therapeutics Inc. stock maintain dividend yield2026 world cup usa national team round of 32 midfield engines build up play match prediction statistical analysis - ulpravda.ru
Is Mineralys Therapeutics Getting To The Heart Of Hypertension With Lorundrostat? - RTTNews
Nasdaq Moves: Is Mineralys Therapeutics Inc stock a safe investment in uncertain marketsJuly 2025 Outlook & Real-Time Volume Spike Alerts - moha.gov.vn
Behavioral Patterns of MLYS and Institutional Flows - Stock Traders Daily
Mineralys Therapeutics Earnings Notes - Trefis
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus - ts2.tech
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.4%What's Next? - MarketBeat
Oversold Conditions For Mineralys Therapeutics (MLYS) - Nasdaq
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a 38% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Simplify Asset Management Inc. Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Commit To Buy Mineralys Therapeutics At $22.50, Earn 16.1% Annualized Using Options - Nasdaq
Mineralys Therapeutics prices $175M stock offering - MSN
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha
Swedbank AB Sells 84,500 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Voya Investment Management LLC Grows Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge - Yahoo Finance
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears - Yahoo Finance
Mineralys Therapeutics, Inc. (MLYS): Exploring a 35% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
If These Biotech Stocks Pull Back, I'll Be Ready to Pull the Trigger - TheStreet Pro
Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial - MSN
(MLYS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Did JAMA’s “Research of the Year” Spotlight on Lorundrostat Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative? - Sahm
Analyst Upgrade: Can Mineralys Therapeutics Inc stock attract ESG capital inflowsEarnings Growth Summary & Weekly Stock Performance Updates - moha.gov.vn
Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS) - The Globe and Mail
Is Mineralys Therapeutics Inc. stock near bottom after decline2025 Technical Patterns & Fast Exit and Entry Strategy Plans - Улправда
Mineralys stock price target raised to $52 by Stifel on strong trial data By Investing.com - Investing.com Nigeria
Stifel Maintains Mineralys Therapeutics (MLYS) Buy Recommendation - Nasdaq
Why Mineralys Therapeutics Inc. stock is in analyst buy zone2025 Fundamental Recap & Fast Entry High Yield Stock Tips - Улправда
Mineralys stock price target raised to $52 by Stifel on strong trial data - Investing.com South Africa
Can Mineralys Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Momentum & Advanced Swing Trade Entry Plans - DonanımHaber
Is Mineralys Therapeutics Inc. stock ready for breakoutIPO Watch & Weekly Return Optimization Alerts - Улправда
Is Mineralys Therapeutics Inc. stock a safe investment in uncertain marketsQuarterly Profit Summary & Daily Technical Stock Forecast Reports - DonanımHaber
JAMA Spotlights Mineralys Trial as Breakthrough for Resistant Hypertension - MyChesCo
Wall Street analysts think Mineralys Therapeutics, Inc. (MLYS) could surge 27.55%: Read this before placing a bet - MSN
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):